Mitoxantrone hydrochloride liposome combined with cytarabine for treating pediatric acute myeloid leukemia with RUNX1∷MTG16 fusion gene: a case report and literature review
10.3760/cma.j.cn121090-20240805-00289
- VernacularTitle:盐酸米托蒽醌脂质体联合阿糖胞苷治疗RUNX1∷MTG16融合基因阳性儿童急性髓系白血病1例及文献复习
- Author:
Shuo LIN
1
;
Benquan QI
;
Lipeng LIU
;
Jigang XIAO
;
Wenyu YANG
;
Xiaofan ZHU
;
Xiaojuan CHEN
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所）、血液与健康全国重点实验室、国家血液系统疾病临床医学研究中心、细胞生态海河实验室，天津 300020
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2024;45(12):1134-1137
- CountryChina
- Language:Chinese
-
Abstract:
This case report presents a patient with pediatric acute myeloid leukemia (AML) with RUNX1∷MTG16, admitted to the Blood Disease Hospital of the Chinese Academy of Medical Sciences in October 2023. He was 13 years old, with a chief complaint of fatigue for 20 days. Bone marrow smear revealed 17.0% blasts, the karyotype was 46,XY,t (16; 21) (q24; q22), molecular biology demonstrated RUNX1∷MTG16 fusion gene, combined with FLT3-ITD mutation. The child was diagnosed with AML (with RUNX1 ∷ MTG16). Complete remission was achieved after chemotherapy induction. The induction therapy regimen was mitoxantrone hydrochloride liposomes combined with cytarabine (MA). The RUNX1 ∷ MTG16 and FLT3-ITD were negative after another MA treatment course. However, the RUNX1 ∷ MTG16 and FLT3-ITD were turning positive during the following intensive treatment, and he then successfully underwent matched sibling donor umbilical cord blood transplantation.
